| TOWER-BIOSECURITY-INC |
TOWER-BIOSECURITY-INC |
92%
|
the Purchaser issued to the Seller shares of common stock of the Purchaser representing approximately 20% of the issued and outstanding equity of the Purchaser |
| CRON |
Cronos Group Inc. |
72%
|
Reciprocal relationship from CRON graph: Reciprocal relationship from DNA graph: Reciprocal relationship from CRON graph: Reciprocal relationship from DNA graph: Reciprocal relationship from CRON gra… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from DNA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DNA graph: t they will deliver to us the items we … |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
t they will deliver to us the items we order on time, or at all. In particular, we rely on Twist for custom DNA synthesis and Thermo Fisher Scientific Inc. and others for certain instruments and cons… |
| ALLONNIA-MOTIF-FOODWORKS-INC |
ALLONNIA-MOTIF-FOODWORKS-INC |
62%
|
ty contribution being expensed in the year that the shares were issued. As of December 31, 2021, the carrying value of the equity method investment in Allonnia has been reduced to 0 . There is no com… |
| ARCAEA-ALLONNIA-LLC |
ARCAEA-ALLONNIA-LLC |
62%
|
on being expensed in 2021. As of December 31, 2021, the carrying value of the equity method investment in Arcaea has been reduced to zero . There is no commitment for the Company to provide further f… |
| BIOMEDIT-ARCAEA-LLC |
BIOMEDIT-ARCAEA-LLC |
62%
|
nts Ginkgo Bioworks Holdings, Inc. Notes to Consolidated Financial Statements equity method investment in BiomEdit to zero . There is no commitment for the Company to provide further financial suppor… |
| BOLT-THREADS-INC |
BOLT-THREADS-INC |
62%
|
. Additionally, the purchase agreement included $ 2.5 million of employee retention payments, which was recognized as compensation expense over the requisite service period. On August 17, 2022, the C… |
| CIRCULARIS-BIOTECHNOLOGIES-INC |
CIRCULARIS-BIOTECHNOLOGIES-INC |
62%
|
utstanding equity interests in Circularis Biotechnologies, Inc., (“Circularis”), a biotechnology company with a proprietary circular RNA and promoter screening platform. The aggregate purchase consid… |
| COOKSONIA-LLC |
COOKSONIA-LLC |
62%
|
the Bayer TDA. The APA, JV Termination Agreement and Bayer TDA were accounted for as a single transaction as they were entered into at the same time and in contemplation of one another, the occurrenc… |
| FGEN-AG |
FGEN-AG |
62%
|
s a result of the sale, the Company deconsolidated all of Altar's assets and liabilities from its consolidated financial statements effective September 30, 2024, and recognized a loss on deconsolidat… |
| JOYN-BIO-LLC |
JOYN-BIO-LLC |
62%
|
idation date, the employee leasing charges were considered related party transactions and have been recognized in the Company's consolidated financial statements. Employee lease expense totaled $ 4.9… |
| SOARING-EAGLE-ACQUISITION-CORP |
SOARING-EAGLE-ACQUISITION-CORP |
62%
|
obability-weighted, and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement as of December 31, 2024 included scenario probabilities ranging f… |
